Future Virology. 2015;10(2):77-88. As shown in Figure 2A, katsumadain A exhibited a high level of self-FL at concentrations similar to or greater than 10 µM when compared with the background ...

Dr David Tovey, Editor-in-Chief, Cochrane, said: "We now have the most robust, comprehensive review on 'neuraminidase inhibitors' that exists. Initially thought to reduce hospitalisations and ...

Recent research has provided valuable insights into the susceptibility of influenza viruses to antiviral drugs, particularly neuraminidase inhibitors (NAIs) and the newer polymerase acidic (PA ...

Choreo LLC acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the fourth quarter, according to the company in its most recent filing with the ...

In a question and answer format, UC Riverside public policy professor Richard Carpiano and medical school professor Dr.

KBC Group NV grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 80.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 10,198 shares ...

University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / ...

University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / Febru ...

Roche is hoping the new drug can breathe new life into its flu franchise, represented by older neuraminidase inhibitor Tamiflu (oseltamivir). That was a $3 billion brand at its peak, but has ...

Antiviral drugs available for the prevention and treatment of influenza include neuraminidase inhibitors (e.g., oseltamivir and zanamivir) and amantadates (e.g., amantadine and rimantadine).

The transcription factor of neuraminidase 3 (NEU3) of DEGs was verified by double ... which is verified by JAK2 inhibitor and NEU3 inhibitor. Conclusion EPO, as a proinflammatory factor, accelerates ...

The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names, and ORLADEYO, an ...